Patients with deleterious germline mutations: A heterogeneous population for pancreatic cancer screening?

Background and Objectives Modest data exist on the benefits of screening and surveillance for pancreatic cancer (PC) in high‐risk individuals. Intraductal papillary mucinous neoplasms (IPMN) are known precursors to PC. We hypothesized that patients with high‐risk deleterious germline mutations have a higher prevalence of IPMN. Methods All patients undergoing prospective screening at a single institution from 2013 to 2019 were reviewed. Results Of 1166 patients screened, 358 (31%) possessed germline mutations and/or family history of PC (mutations n = 201/358, 56%, family history n = 226/358, 63%) (median follow‐up 2.7 years). IPMN was found in 127 patients (35.5%). The prevalence of IPMN in mutation carriers (18%) was higher than in the general population (p